Collects spinal fluid and blood samples from people with Huntington's disease
Collects spinal fluid and blood samples from people with Huntington's disease at different stages.
Plain-language title generated from the registry record
Registry title: HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Key facts
- Where
- Lisbon, PortugalSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 11 and 75 years old?
Source: NCT02855476, who can take part
Where in Portugal
- Gulbenkian Institute of Molecular MedicineLisbon, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University College, London
- Trial code
- NCT02855476
- Record updated
- 27 April 2026
- Original description
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.Read full original descriptionShow less
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Inclusion: Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD); Enroll HD participant; Capable of consenting or have a legal representative (parent/guardian for juveniles); Capable of complying with study procedures; All participants other than family and community controls must have had a genetic test for HD.
Exclusion: Drug trial within 30 days of any sampling visit; Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days); Antiplatelet or anticoagulant therapy within 14 days; Needle phobia, headache, spinal surgery / deformity; Drug / alcohol abuse; Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days; Clotting or bruising disorder; Significant comorbidity; Screening blood test abnormalities >10% outside normal range; Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential; Predictable non compliance or unwillingness.